New shot for tough blood cancers enters first human tests
NCT ID NCT07294300
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the drug as a shot under the skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart Treatment-Resistant blood cancer?
- Immune cells engineered to fight lymphoma enter human testing
- New combo therapy shows promise for tough lymphoma cases
- New cell therapy takes aim at Hard-to-Treat blood cancers
- New study aims to crack the code of treatment resistance in lymphoma
- New injection shows promise for Hard-to-Treat cancers